NCT01173055View on ClinicalTrials.gov

A Study to Evaluate the Effects of Milnacipran on Pain Processing and Functional MRI in Patients With Fibromyalgia

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Fibromyalgia
Interventions
DRUG

milnacipran

Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.

DRUG

Placebo

Placebo will be given orally twice daily in tablet form at different times during the course of the study.

Trial Locations (1)

48106

University of Michigan, Chronic Pain and Fatigue Research Center, Ann Arbor

Sponsors

Collaborators (1)

Forest Laboratories
All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

University of Michigan

OTHER